Qiagen grounds drug discovery agents in curated knowledge
Qiagen N.V. is betting that drug discovery agents need a trustworthy knowledge foundation as much as capable models. For biopharma companies, that means giving agents information with clear provenance and enough context to support their answers. Knowledge graphs can provide that context layer for AI agents, according to Iman Bhattacharya, senior global product marketing manager […] The post…
Qiagen, a biotechnology company, is emphasizing the importance of reliable knowledge foundations for drug discovery agents, alongside advanced AI models. Senior global product marketing manager Iman Bhattacharya highlighted that knowledge graphs can provide the necessary context layer for AI agents. However, human curation remains a cornerstone of their approach.
Bhattacharya stressed that while AI is here to enhance capabilities, it must be deeply grounded in human-curated knowledge. Qiagen's bioinformatics arm has been manually curating biomedical data for over 25 years, involving more than 150 experts with MD and PhD degrees. This curated knowledge now serves as the backbone for Qiagen's Discovery Platform, which incorporates the Model Context Protocol (MCP) and an agentic Discovery Explorer.
The company has also partnered with Nvidia to enhance graph-based AI for drug discovery. The objective is not to isolate these components but to integrate them into a cohesive system aimed at improving the accuracy and traceability of AI-generated outputs. Pharma customers measure return on investment based on the speed at which accurate drug indications are identified, and AI agents producing inaccurate or fabricated results can undermine this goal.
Written by urgent.news from SiliconANGLE's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
